Vertex Pharmaceuticals Files 8-K on Financials
Ticker: VRTX · Form: 8-K · Filed: Nov 4, 2024 · CIK: 875320
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: VRTX
TL;DR
Vertex Pharma dropped an 8-K on Nov 4th covering financials. Check it for the latest numbers.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's ongoing business activities and financial reporting requirements.
Why It Matters
This filing provides investors with crucial updates on Vertex Pharmaceuticals' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- Massachusetts (location) — State of incorporation
- 000-19319 (other) — SEC File Number
- 04-3039129 (other) — I.R.S. Employer Identification No.
- 50 Northern Avenue Boston, Massachusetts 02210 (location) — Principal executive offices address
- November 4, 2024 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Vertex Pharmaceuticals' 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on November 4, 2024.
What is Vertex Pharmaceuticals' principal executive office address?
The principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts 02210.
What is the SEC file number for Vertex Pharmaceuticals?
The SEC file number for Vertex Pharmaceuticals is 000-19319.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-11-04 16:02:42
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20241104.htm (8-K) — 25KB
- ex-991_q32024.htm (EX-99.1) — 234KB
- 0000875320-24-000221.txt ( ) — 406KB
- vrtx-20241104.xsd (EX-101.SCH) — 2KB
- vrtx-20241104_lab.xml (EX-101.LAB) — 21KB
- vrtx-20241104_pre.xml (EX-101.PRE) — 12KB
- vrtx-20241104_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 4, 2024, we issued a press release in which we reported our consolidated financial results for the three and nine months ended September 30, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated N ovember 4 , 2024. 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: November 4, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer